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SHORT COMMUNICATION
Peripheral blood lymphocyte number and phenotype prior to therapy
correlate with response in subcutaneously applied rIL-2 therapy of renal
cell carcinoma
R.A.J. Janssen', D.Th. Sleijfer2, A.A. Heijnl, N.H. Mulder2, T.H. The' & L. de Leijl
Departments of'Clinical Immunology and 2Medical Oncology, University Hospital Groningen, The Netherlands.
Summary The phenotype of peripheral blood lymphocytes of 27 renal cell carcinoma patients before and at
the end of subcutaneously given rIL-2 therapy was determined by two colour flow cytometry. Therapy induced
changes in peripheral blood leucocyte composition and phenotypes were comparable to those reported for
intravenously given rIL-2. The present paper shows a correlation between the 'activation status' of the patient
before therapy and eventual response.
The therapeutical effects of recombinant interleukin-2 (rIL-2)
therapy look promising in the case of renal cell carcinoma
(RCC) and melanoma (Rosenberg et al., 1987; West et al.,
1987).
Most of the interleukin-2 therapies so far, involved the
intravenous administration of high dose rIL-2, causing severe
side effects. In our clinic, rIL-2 was administered subcuta-
neously (s.c.) which avoided severe side effects, whereas
clinical results were comparable to the ones involving intra-
venous (i.v.) administration of rIL-2 (Sleijfer et al., 1990;
1992). The immunomodulatory effects of subcutaneously
administered rIL-2 still remain to be investigated.
The present paper gives data on the 'activation status' of
the main peripheral blood lymphocyte subpopulations (helper
T cells, cytotoxic T cells and NK cells) in 27 RCC patients
by determining the expression of the activation marker HLA-
Dr on these lymphocytes before and after s.c. rIL-2 therapy
(day 35 and day 40).
Materials and methods
Patients and therapeutic protocol
All patients (27; 16 male and 11 female) had evaluable
metastatic renal cell carcinoma (RCC). Their average age was
59 (range 41-74). Patients participated in a phase II study of
treatment with subcutaneous rIL-2 (Sleijfer et al., 1990;
1992), when informed consent was obtained. Patients receiv-
ed a 5-day cycle of Cetus rIL-2 (EuroCetus, Amsterdam, The
Netherlands) every week for 6 consecutive weeks. During the
first 5-day cycle 18 million IU rIL-2 were given once daily; in
the following cycles the dose in the first 2 days was reduced
to 9 million units. Treatment results were: two complete
remissions (CR), four partial remissions (PR), seven patients
had progressive disease (PD), and 14 patients showed stable
disease (SD). A complete response required disappearance of
all evidence of tumour for a minimum of 4 weeks, a partial
response was registrated when a 50% or greater decrease in
the sum of the products of all diameters of evaluable lesions
was reached; patients with a response less than partial or an
increase of less than 25% were classified as stable disease.
Progression was defined as an increase of more than 25% or
the development of new lesions.
Monoclonal antibodies
All monoclonal antibodies (Becton Dickinson, Mountain
View, CA, USA) were directly conjugated with phycoerythrin
(PE) or fluorescein-isothiocyanate (FITC). Monoclonal anti-
bodies (mAb) used were aleu4 (CD3), aleu3 (CD4), aleu2
(CD8), aleul9 (CD56), and xHLA-Dr.
Immunostaining ofcells andflow cytometry
Peripheral blood lymphocytes of RCC patients were analysed
before (day 0) and at the end of rIL-2 therapy (days 35 and
40). One hundred pl of EDTA blood was resuspended in
20 gl of mAb preparation (containing 101l of each mAb)
and incubated at room temperature (RT) for 15 min. Two ml
of FACS lysing solution (Becton Dickinson) was added and
the cells were incubated for an additional 10min. Subse-
quently, the solution was centrifugated at 1000 g for 2 min
and the cells were washed in 2 ml of phosphate buffered
saline supplemented with 15 U ml-' heparin (PBS/heparin)
and resuspended in 150 ll of the same solution.
The samples were immediately analysed on a FACStar
(Becton Dickinson) with the laser tuned at 488 nm. Lympho-
cytes were gated using standard FSC/SSC settings.
Statistics
Statistical significant differences were determined using the
Wilcoxon test or the distribution free sign test as indicated. P
values of <0.05 were considered significant.
Results
Hematological changes during sc rIL-2 treatment
In all patients, in each cycle, during rIL-2 administration the
absolute number of lymphocytes decreased, whereas during
the 2 days without rIL-2 a rapid and large increase of the
absolute number of lymphocytes was found. During therapy
all patients developed highly elevated numbers of eosinophils
(from 0.28*106+0.19*106 per ml on day 0 to a peak of
7.9*106±4.0*106 per ml on day 19).
Changes in peripheral blood lymphocyte composition
The changes in peripheral blood composition of 20 patients
was determined. Ten patients were analysed on day 0 and
day 40, seven on day 0 and day 35, and three on day 0, 35
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and 40. These patients were ordered in two groups. Group I
consisted of 13 patients analysed on day 0 and day 40
(lymphopenic phase) and group II consisted of 10 patients
analysed on day 0 and day 35 (rebound phase preceding the
last rIL-2 cycle). Table I shows that, at the end of therapy,
both the relative and absolute amounts of CD56+ cells had
increased significantly, both on day 35 (P<0.01, sign test) as
well as on day 40 (P<0.01) when compared with day 0
within each group. In contrast, the relative amount of CD3+
cells had decreased significantly (P<0.01) in both groups
when compared to day 0. This decrease was due to decreases
in both the relative amounts of CD8bright+ cells and CD4+
cells. Still, the absolute numbers of CD3+ cells had increased
significantly (P<0.05) from day 0 to day 35 (predominantly
due to an increase of the CD4+ cells, Table I), while there
was no significant change in the absolute amount of CD3+
cells on day 40 compared to day 0.
'Activation status' ofthe subpopulations
Table II shows that the absolute numbers of various sub-
populations expressing HLA-Dr had increased during rIL-2
therapy. Table II also shows that the activation marker
HLA-Dr became predominantly expressed on CD56+ cells.
Both on day 35 and day 40 the relative and absolute
numbers of CD56+HLA-Dr+ cells had increased significantly
compared to day 0 within each group.
Lymphocyte 'activation status' and response to therapy
Two out of the 27 patients showed complete remission and
four showed a partial remission. Seven patients had progres-
sion of disease, whereas 14 were qualified as stable. To
determine a possible correlation between clinical outcome
and immunological changes, patients were grouped according
to these three catagories (responders, progressive and stable)
and immunological data were compared.
No correlation was found when data obtained at the end
of the therapy were compared with each other. However, the
six patients with remission showed significantly higher
absolute and relative numbers of lymphocytes just before the
first rIL-2 administration (Table III) than the patients with
no remission (P<0.01; Wilcoxon test). In addition, they had
significantly higher absolute amounts of CD8bright+HLA-
Dr+ (P<0.01), CD4+HLA-Dr+ (P=0.01), and CD56+
HLA-Dr+ (P<0.02) cells than the patients who did not
respond (SD, PD, see Table III).
Discussion
Many groups have examined the immunomodulatory effects
in RCC patients and melanoma patients (Lotze et al., 1987;
Ellis et al., 1988; Weil-Hillman et al., 1989; Urba et al., 1990;
Favrot et al., 1990) receiving rIL-2 intravenously. In the
present paper the immunomodulatory effects of rIL-2 therapy
in renal cell carcinoma patients receiving rIL-2 sub-
cutaneously were studied.
Each time a new cycle of treatment was started, the
abolute lymphocyte count decreased rapidly, whereas a quick
increase (rebound lymphocytosis) was found when administ-
ration of rIL-2 was stopped between day 5-7 of each cycle.
All patients showed an increase in the absolute eosinophil
count in the peripheral blood. These results, obtained with
subcutaneously applied rIL-2, extend the findings of others
(Sondel et al., 1988) monitoring patients treated int-
ravenously with rIL-2. So, the results might be taken as an
indication that subcutaneously given rIL-2, despite its con-
siderably lower toxicity as compared to intravenously given
rIL-2, has an effect on the immune system comparable to i.v.
given rIL-2.
The NK population showed the highest increase in relative
and absolute numbers. This is in agreement with the results
reported for intravenously administered rIL-2 (Weil-Hillman
et al., 1989; Ellis et al., 1988), although the increase in the
relative and absolute numbers of the NK population during
s.c. administration was less pronounced. In addition, the
relative number and absolute number of NK cells (CD56+)
expressing HLA-Dr had increased significantly.
Until now, no good correlation between phenotypical
changes in the periphal blood and response to rIL-2 therapy
has been found (Favrot et al., 1990). One study concerning
i.v. administered rIL-2, however, showed a positive correla-
tion between remission and lymphocytosis (West, 1989).
The study presented here extends the number of possible
parameters correlated with response. It appears that high
numbers of lymphocytes and high numbers of cells express-
ing the activation marker HLA-Dr prior to therapy are a
prognostically favorable parameter (Table III). Interestingly,
the two patients with complete remissions showed con-
siderably higher numbers of CD8bright and CD56 positive
cells expressing HLA-Dr. These high numbers of activated
CD8bright cells might reflect a more immunogenic tumour in
these patients. Summarising, the study presented here shows
that subcutaneously administered rIL-2 induces immuno-
logical changes comparable to intravenously administered
Table I Changes in peripheral blood composition
CD3+ CD4+ CD8bright+ CD56+CD3- Day oftreatment % x 103ml-1 % x103 ml-, % x 103mlt I % x103 ml-,
Group I (n = 13)
0 71±9 906±359 48±11 605±295 24±10 291±159 13±7 163±105
40 47±11I 831±362 34±13d 504±248 14±5f 218±135 38±12c 578±283C Group II (n = 10)
0 70±8 974±561 43±10 606±408 29±9 392±236 12±4 168±111 35 54+±14 2351±1999a 39±13 1696±1422C 17±8d 714±638 36±13C 1628±1327C
asignificant increase compared to day 0, P <0.05, bp < 0.02, CF < 0.01. dSignificant decrease compared to day 0, P < 0.05, ep , 0.02, fP < 0.01. Statistical significance determined by distribution free sign test
Table II Changes intheactivationstatusofvarioussubpopulations. Forstatistical significance, see
Table II
CD4+HLA-Dr+ CD8bright+HLA-Dr+ CD56+HLA-Dr+
Day oftreatment % x103mlt I % X103ml- I % X103mlt I
Group I (n = 13)
0 4±2 50±36 3±2 34±22 2±1 18±13
40 6±4 95±72a 3±2 45±39 19±7c 282± 141c
Group II (n = 10)
0 4±2 61±51 5±4 65±98 3±3 42±54
35 8±5 316±204c 4±3 206± 183a 17± 1c 736±967CIMMUNOMODULATORY EFFECTS OF s.c. rIL-2 THERAPY 1179
TableIII Absoluteandrelativenumberoflymphocytesandlymphocytesubpopulationsexpressing
HLA-Dr as determined on day 0
Absolute number Relative number CD8bright+ CD4+ CD56+
Patient oflymphocytes oflymphocytes HLA-Dr+ HLA-Dr+ HLA-Dr+
1CR 2.8a 29b 154c 113c 84c
2 CR 2.1 24 248 144 165
3 PR 1.7 35 51 85 17
4 PR 1.8 33 95 73 52
5 PR 1.3 21 52 52 26
6 PR 1.3 30 ND ND ND
Average 1.8+±06d 28.7± 5.3d 120.0± 83.0d 93.4± 31.9d 68.8± 59.8e
7 PD 0.6 14 24 26 13
8 PD 0.5 7 10 25 28
9 PD 1.4 31 42 28 14
10 PD 1.3 10 13 26 13
11PD 1.0 13 ND ND ND
12PD 1.1 10 44 22 33
13 PD 2.1 22 ND ND ND
Average 1.1 ±0.5 15.3±8.4 26.6± 15.9 25.4±2.2 20.2±9.6
14 SD 1.1 21 88 33 33
15 SD 1.4 27 14 14 14
16SD 1.4 18 70 126 14
17 SD 1.2 16 ND ND ND
18 SD 0.6 7 18 24 30
19 SD 1.2 21 36 36 12
20SD 1.2 12 24 60 12
21 SD 0.9 12 18 27 18
22 SD 1.4 17 ND ND ND
23 SD 0.7 7 ND ND ND
24 SD 0.9 18 54 54 18
25 SD 0.5 7 15 15 10
26SD 2.4 29 48 96 48
27 SD 0.5 4 5 20 10
Average 1.1±0.5 15.4±7.7 35.5±26.5 45.9± 36.0 19.9±11.0
aMillionsml-'; bPercentage ofall leucocytes; cThousands ml .Average numbers werecalculated
foreachgroupofpatients. dSignificantlyhigherthannon-responders (P < 0.01);eSignificantlyhigher
than non-responders (P < 0.02). Statistical significance was calculated using the Wilcoxon test
(two-sided).
rIL-2. We have already shown that s.c., in contrast to i.v.,
administered rIL-2, induces no severe side effects, whereas
clinical responses are comparable (Sleijfer et al., 1990; 1992).
Most importantly, this report shows that the 'activation
status' of the patient prior to therapy is related to the
outcome of therapy.
References
ELLIS, T.M., CREEKMORE, S.P., MCMANNIS, J.D., BRAUN, D.P.,
HARRIS, J.A. & FISHER, R.I. (1988). Appearance and phenotypic
characterization of circulating leul9+ cells in cancer patients
receiving recombinant interleukin 2. Cancer Res., 48, 6597-6602.
FAVROT, M.C., COMBARET, V., NEGRIER, S., PHILIP, I., THIESSE, P.,
FREYDEL, C., BIJMANN, J.T., FRANKS, C.R., MERCATELLO, A. &
PHILLIP, T. (1990). Functional and immunophenotypic
modifications induced by interleukin-2 did not predict response to
therapy in patients with renal cell carcinoma. J. Biol. Response
Mod., 9, 167-177.
LOTZE, T.M., CUSTER, M.C., SHARROW, S.O., RUBIN, L.A., NELSON,
D.L. & ROSENBERG, S.A. (1987). In vivo administration of
purified human interleukin-2 to patients with cancer: develop-
ment of interleukin-2 receptor positive cells and circulating solu-
ble interleukin-2 receptors following interleukin-2 administration.
Cancer Res., 47, 2188-2195.
ROSENBERG, S.A., LOTZE, M.T., MUUL, L.M., CHANG, A.E., AVIS,
F.P., LEITMAN, S., LINEHAN, M., ROBERTSON, C.N., LEE, R.E.,
RUBIN, J.T., SEIPP, C.A., SIMPSON, C.G. & WHITE, D.E. (1987). A
progress report on the treatment of 157 patients with advanced
cancer using lymphokine-activated killer cells and interleukin-2 or
high-dose interleukin-2 alone. N. Engi. J. Med., 316, 889-897.
SLEIJFER, D.Th., JANSSEN, R.A.J., WILLEMSE, P.H.B., MARTENS, A.,
DE LEIJ, L., DE VRIES, E.G.E. & MULDER, N.H. (1990). Low-dose
regimen of interleukin-2 for metastatic renal carcinoma. Lancet,
335, 1522-1523.
SLEIJFER, D.Th., JANSSEN, R.A.J., BUTER, J., WILLEMSE, P.H.B., DE
VRIES, E.G.E. & MULDER, N.H. (1992). Phase II study ofsubcutan-
eous interleukin-2 in unselected patients with advanced renal cell
cancer on an outpatient basis. J. Clinical Oncol., 10, 1119-1123.
SONDEL, P.M., KOHLER, P.C., HANK, J.A., MOORE, K.H., ROSEN-
THAL, N.S., SOSMAN, J.A., BECHHOFER, R. & STORER, B. (1988).
Clinical and immunological effects of recombinant interleukin 2
given by repetitive weekly cycles to patients with cancer. Cancer
Res., 48, 2561-2567.
URBA, W.J., STEIS, R.G., LONGO, D.L., KOPP, W.C., MALUISH, A.E.,
MARCON, L., NELSON, D.L., STEVENSON, H.C. & CLARK, J.W.
(1990). Immunomodulatory properties and toxicity of interleukin
2 in patients with cancer. Cancer Res., 50, 185-192.
WEIL-HILLMAN, G., FISCH, P., PRIEVE, A.F., SOSMAN, J.A., HANK,
J.A. & SONDEL, P.M. (1989). Lymphokine-activated killer activity
induced by in vivo interleukin 2 therapy: predominant role for
lymphocytes with increased expression ofCD2 and leul9 antigens
but negative expression of CD16 antigens. Cancer Res., 49,
3680-3688.
WEST, W.H., TAUER, K.W., YANELLI, J.R., MARSHALL, G.D., ORR,
D.W., THJURMAN, G.B. & OLDHAN, R.K. (1987). Constant
infusion recombinant interleukin-2 in adoptive immunotherapy of
advanced cancer. N. Engl. J. Med., 316, 898-905.
WEST, W. (1989). Continuous infusion recombinant interleukin-2
(rIL-2) in adoptive cellular therapy of renal carcinoma and other
malignancies. Cancer Treatment Rev., 16 (Supplement A), 83-89.